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PERSPECTIVES

Cancer Immunotherapy Comes of Age
Michael Karsy & Bryant England

I

magine training the body to attack cancer. As defined by the National Cancer Institute, cancer is a
process by which abnormal cells divide without
control and are able to invade other tissues.1 This
complex process is governed by genetic mutation,
which results in cancer cells losing their resemblance
to the normal cells they are ultimately derived from,
overcoming built-in cellular mechanisms to prevent
runaway growth, inducing neoangiogenesis or the
formation of new blood vessels, as well as eventual
metastasizing to foreign tissue sites.1 Importantly,
cancers develop an ability to evade the body’s immune system through a variety of mechanisms, such
as changing surface proteins that immune cells normally use to home in on foreign cells, accumulation of
regulatory T-cells (Treg) that suppress the immune
response, as well as secretion of specific immune signaling cytokines (e.g., interleukin 6 [IL-6] and 10 [IL10]) to inhibit lymphocytes that normally kill tumor
cells.2,3 So if cancer has developed an ability to subvert the immune system, how is it possible to overcome this mechanism of tumor self-preservation?
The burgeoning field of immunotherapy may hold
some answers in creating novel treatments for cancer
as well as new ways of thinking about this old disease.

The immune system is a complexity overcome by the
cleverness of cancer cells. This system has been classically divided into the innate and adaptive immune
systems.2-4 The innate immune system is the first-line
defense system involving anatomical barriers to infection, cytokine-mediated recruitment of immune cells,
as well as complement proteins, (molecules used to
identify and destroy foreign cells while recruiting immune cells). Other players in the innate immune system include macrophages that ingest and destroy foreign cells, neutrophils that secrete destructive enzymes, basophils and eosinophils that aid in eliminating parasites, as well natural killer T-cells that target
foreign cells, including tumor cells. One of the ultimate results of the innate immune system is the activation of the adaptive immune system via antigen
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presenting cells. The adaptive immune system consists predominantly of CD8+ cytotoxic T-cells that monitor and destroy infected cells, CD4+ helper T-cells that
identify foreign antigens to signal antibody production, and B-cells that are involved in sensing antigens
and forming antibodies. This system also includes
gamma/delta T-cells that share characteristics of CD8+
and CD4+ T-cells. Despite each of these intricate, wellregulated components, cancer cells have developed
methods to overcome nearly every mechanism of the
immune system.

Cancer immunotherapy is broadly defined as the ability to induce the innate and adaptive immune system
to neutralize neoplastic cells. Multiple methods have
developed over the past 50 years with the most interesting clinical applications unveiled only recently.
These include non-cellular methods such as antibodies and drugs to regulate the immune system (Figure
1) as well as cellular based techniques to manipulate
the immune system such as adoptive cell transfer
(ACT) and tumor vaccines (Figure 2). These methods
have shown mixed effects in different cancers again
reaffirming the immense heterogeneity of cancer and
difficulty in treating this disease.

A straightforward strategy to treat cancer includes
inducing the immune system. Administration of the
body’s own signaling molecules (cytokines such as IL2 or interferon-α) has been shown to stimulate the
immune system to fight cancer (Figure 1A).5 In fact,
pegylated interferon-α2b was approved by the Federal Drug Administration (FDA) in 2011 for the treatment of melanoma.6 These initial approaches have
been expanded by recent knowledge regarding immune-modulating antibodies and cell signaling. Tumor-specific monoclonal antibody, generation is an
approach that uses purified antibodies generated in
the lab towards a specific tumor cell surface target.7
Rituximab (Biogen Idec/Genentech, San Francisco, CA)
is a monoclonal antibody used to target CD20 cell re-
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Figure 1: Non-cellular methods of immunotherapy. Various methods of immunotherapy using non-cellular
means are shown. A) Treatment with interleukin-2 (IL-2) or interferon-α can stimulate the immune system
to fight cancer. Examples include the use of pegylated interferon-α2b in the treatment of melanoma. B)
Designed tumor-specific monoclonal antibodies can target tumor cells via induction of an immune response
(Antibody-mediated cell-dependent cytotoxicity) or via activation of the immune system’s complement cascade (Complement activation). Examples include Rituximab for the treatment of non-Hodgkin cell lymphoma and chronic lymphocytic leukemia as well as Trastuzumab in the treatment of breast cancer. C) Immune-modulating antibodies are used to target co-regulatory proteins that allow T-cells to interact with tumor cells or antigen presenting cells. Examples include Ipilimumab and Tremlimumab for the treatment of
metastatic melanoma. D) Antibody-drug conjugates and antibody-toxin conjugates are being developed to
target tumor cells. Antibody-radioisotope conjugates may allow for earlier tumor diagnosis. Bispecific
monoclonal antibodies are useful for localizing the body’s immune cells to tumor cells.

ceptors which has been approved by the FDA in the
treatment of non-Hodgkin cell lymphoma and chronic
lymphocytic leukemia, as well as several nononcological diseases.8 Recent studies have surprisingly shown that this antibody helps induce the immune
system to kill targeted tumor cells in a process known
as antibody-dependent cell-mediated cytotoxicity
(ADCC) (Figure 1B).9
The drug Trastuzumab
(Genentech, San Francisco, CA), also known as Herceptin and used to target the Her2/Neu growth factor
receptor in the treatment of breast cancer, has also
been shown to mediate ADCC in addition to its well
known effects on altering growth factor signaling of
targeted cancer cells.10

Other novel uses of monoclonal antibodies include

immune-modulating antibodies.
Two new compounds, Ipilimumab (Bristol-Myers Squibb, Princeton,
NJ) and Tremlimumab (Pfizer, New York, NY), have
been shown to target CTLA-4 (Figure 1C)11. Normally
CTLA-4 is a co-regulatory receptor on T-cells that
binds to molecules B7-1 and B7-2 found on dendritic
or tumor cells and inhibits the immune system, which
can allow cancer cells to escape targeting. Ipilimumab and Tremlimumab disrupt this inhibition and
have shown response rates of 10-15% with metastatic
melanoma and renal cell carcinoma. 12 Ipilimumab
has been FDA-approved as a first-line therapy for metastatic melanoma based on promising phase III trials.13 Even newer therapies are looking at additional
co-regulatory immune-checkpoint targets such as programmed cell death 1 (PD1) which are present in
many cancers and may result in a more universal on-
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Figure 2: Cell-based methods of immunotherapy towards cancers. Various methods of immunotherapy using cellular means are shown. A) Adoptive cell transfer (ADT) is demonstrated. Tumor infiltrating lymphocytes are extracted from patients, expanded ex vivo in laboratory cultures, and reinfused back to patients.
Engineered T-cells can also be generated in cultures before reinfusion. B) Cancer vaccines are shown. Tumor cells are extracted from patients and specific tumor proteins are extracted before either being reinjected into patients or used to sensitize patient-derived dendritic cells to target tumors. Examples include
Spuleucel-T used in the treatment of hormone-resistant prostate cancer.

cological therapy.6,14 The ability of bifunctional antibody-like molecules to bind cancer cells and retarget
T-cells towards cancer cells (Figure 1D)15 or use antibody-drug/antibody-toxin conjugates to directly target
individual cancer cells (Figure 1D)16 is also an area of
open investigation. Antibody-radioisotope conjugates
have also been investigated as methods to diagnose
tumors earlier as well as identify disease progression
sooner than current modalities. These methods suggest that non-cellular based techniques to regulate the
immune system can be potent ways of treating cancer.

One form of immunotherapy that has gained momentum in recent years includes adoptive cell transfer
(ACT). This technique utilizes anti-tumor T-cells that
are manipulated ex vivo and then infused into a patient, in a similar method to bone marrow transplantation. In one study, tumor infiltrating lymphocytes
obtained from patients, expanded ex vivo in a lab,
24
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and then re-infused in patients with metastatic melanoma showed that in addition to standard therapy, a
clinical response of 34-72% was seen (Figure 2A).17
Therapies using such multicellular treatments have
shown greater efficacy than therapy with purified single cells, again highlighting the heterogeneity of cancers and their surface markers in striving to achieve
personalized therapy.18 However, the limitation of
ACT involves the cumbersome cell-extraction process.
Newer approaches utilize engineered T-cell receptors
inserted into lab cultured CD4+ and CD8+ peripheral
lymphocytes that can be transfused into patients.19
ACT can achieve tumor-inhibiting activity so long as a
patient’s tumor possesses the required target. Combinations of ACT treatments along with standard treatments are being investigated in various early phase
clinical trials for some cancers.20

One of the most exciting avenues in immunotherapy
is the development of cancer vaccines. Initially set-
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back by a variety of early clinical trial failures in the
1960s, this approach has generated renewed interest
along with a recent FDA-approved treatment. Cancer
vaccines involve the administration of tumor proteins
to generate an immune response or immune cells (i.e.
dendritic cells) sensitized to tumor proteins (Figure
2B). Spuleucel-T/Provenge (Dendreon, Seattle WA),
FDA-approved in 2010 for the treatment of advanced
hormone-resistant prostate cancer, involves inoculating patient-derived peripheral blood mononuclear
cells with prostatic acid phosphatase linked to granulocyte macrophage colony-stimulating factor – essentially training a patient’s own cells to target prostate
cancer specifically.21 In phase III trials, Spuleucel-T
resulted in a 4-month overall survival benefit; The
cost of this treatment, however, has been estimated to
be approximately $100,000, which may limit its eventual application.22 Vaccines towards melanoma23,
high-grade glial24,25, breast26, pancreatic27, lung28 cancers are currently in development. New knowledge of
immune regulation in cancer has improved the efficacy of these approaches by using improved target antigens, high quantities of antigens to sensitize immunity, and proper co-stimulatory signals to activate immune cells.

The field of immunotherapy is emerging significantly
as a viable option in the treatment of cancer. Much
work has yet to be done before this dream can become a reality for many patients. In addition, new
developments have dramatically altered the concept
that cancers have unilaterally circumvented the immune system. Instead, various methods of inducing
the immune system to fight cancer have been developed, methods which will hopefully act as precursors
for the development of similar methods in the near
future.
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